Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What CAGR And Valuation Are Anticipated For The Biomarker Clinical Phase Outsourcing Services Market?

There has been a significant increase in the size of the biomarker clinical phase outsourcing services market in recent times. From $9.71 billion in 2024, it is projected to escalate to $11.91 billion in 2025, boasting a compound annual growth rate (CAGR) of 22.7%. Factors contributing to this trend include increased government initiatives and financings, heightened application of biomarkers in diagnosis, a surge in R&D funding by the government, quick progression in technologies such as genomics, proteomics, and imaging, and a growing need for cancer biomarkers.

Projected expansion in the biomarker clinical phase outsourcing services market is anticipated to be substantial, with expectations reaching $25.87 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 21.4%. Factors such as escalating biomarker usage in numerous clinical trial phases, an increased demand for precision medicines, a surge in the acceptance of companion diagnostics, and a rising need for personalized treatment contribute to this expected growth. Over the forecast period, notable trends will likely consist of enhanced parameters for clinical trials, a focus on diagnostics in clinical phases, swift developments in biomarker technology, increased governmental efforts and funding, as well as technological advancements.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15740&type=smp

What Are The Primary Factors Supporting The Biomarker Clinical Phase Outsourcing Services Market Expansion?

The growth of the biomarker clinical phase outsourcing services market is set to be fuelled by the surge in clinical trials. Clinical trials, which are research studies involving humans to assess new medical treatments, interventions or diagnostic procedures’ safety and effectiveness, are seeing an increase due to advancements in medical research. Other contributing factors include the escalating occurrences of chronic diseases, augmented funding from both public and private sectors, and the escalating demand for cutting-edge treatment options and therapies. Outsourcing providers are often equipped with specialized expertise in biomarker discovery, validation, and analysis, which markedly improves the integrity and quality of the biomarker data collected during the trial. As an illustration, data from the United States National Library of Medicine in May 2023 showed an increase in registered clinical trials from 399,499 in 2022 to 437,533 spanning all 50 states and 221 countries. Moreover, it was reported that 140,492 studies (31%) are registered solely in the United States, while a chunkier 53% (241,498 studies) are located outside of the U.S. Thus, the uptrend in clinical trials will serve to augment the growth of the biomarker clinical phase outsourcing services market.

Which Segments Define The Structure Of The Biomarker Clinical Phase Outsourcing Services Market?

The biomarker clinical phase outsourcing servicesmarket covered in this report is segmented –

1) By Type: Surrogate Endpoints; Predictive Biomarker; Prognostic Biomarker; Safety Biomarker; Other Biomarker Types

2) By Service Type: Biomarker Validation; Biomarker Testing Services; Biomarker Sample Analysis

3) By Therapeutic Area: Oncology; Neurology; Cardiology; Autoimmune Diseases; Other Therapeutic Areas

4) By End-User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutions

Subsegments:

1) By Surrogate Endpoints: Tumor Marker-Based Endpoints; Imaging-Based Endpoints; Genetic or Genomic Markers

2) By Predictive Biomarker: Genetic Predictive Biomarkers; Protein Predictive Biomarkers; Metabolomic Predictive Biomarkers

3) By Prognostic Biomarker: Cancer Prognostic Biomarkers; Cardiovascular Prognostic Biomarkers; Neurological Prognostic Biomarkers

4) By Safety Biomarker: Toxicity Biomarkers; Adverse Drug Reaction Biomarkers; Drug Interaction Biomarkers

5) By Other Biomarker Types: Inflammation Biomarkers; Infectious Disease Biomarkers; Autoimmune Disease Biomarkers

Which Long-Term Trends Will Play A Crucial Role In The Biomarker Clinical Phase Outsourcing Services Market?

Leading enterprises in the field of biomarker clinical phase outsourcing are prioritizing advancements in high-throughput flow cytometry and ELISpot testing to secure a competitive advantage. Both high-throughput flow cytometry and ELISpot testing serve as essential tools for biomarker analysis, providing quick and accurate evaluations of immune responses and cellular markers. For example, Celerion Inc., an American biotechnology outsourcing company, widened its service breadth to include GLP/GCP compliant molecular and cell biology tests in November 2022. This strategic enhancement in Celerion’s capabilities aims to bolster its support to clients across the drug development lifecycle, starting from early clinical research to regulatory submissions. The inclusion of GLP/GCP-compliant molecular and cell biology tests, like pharmacokinetic (PK), pharmacodynamic (PD), and biomarker analysis, allows Celerion to offer a more inclusive suite of services. Such an expansion from Celerion equips its clients with the ability to generate high-grade data in alignment with regulatory standards, hence accelerating the production of new medicines.

Who Are The Primary Market Leaders In The Biomarker Clinical Phase Outsourcing Services Market?

Major companies operating in the biomarker clinical phase outsourcing services market are Thermo Fisher Scientific Inc., Labcorp Drug Development Inc., ICON plc, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Syneos Health Inc., Intertek Group plc, Charles River Laboratories International Inc., Parexel International Corporation, QIAGEN N.V., Medpace Inc., Bioclinica Inc., Evotec SE, GenScript Biotech Corporation, Precision for Medicine Inc., BioAgilytix Labs LLC, Celerion Inc., Frontage Laboratories Inc., SomaLogic Inc., Selvita S.A., BioIVT LLC, Discovery Life Sciences LLC, Metabolon Inc., Caprion Proteomics Inc., Canopy Biosciences LLC

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/biomarker-clinical-phase-outsourcing-services-global-market-report

What Regional Factors Are Accelerating Growth In The Biomarker Clinical Phase Outsourcing Services Market?

North America was the largest region in the biomarker clinical phase outsourcing services market in 2024. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15740&type=smp

Browse Through More Reports Similar to the Global Biomarker Clinical Phase Outsourcing Services Market 2025, By The Business Research Company

Bioadhesives Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bioadhesives-global-market-report

Biosurfactants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosurfactants-global-market-report

Probiotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/probiotics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model